Anna Bucsics
Overview
Explore the profile of Anna Bucsics including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cavaller-Bellaubi M, Hughes-Wilson W, Kubinova S, van de Casteele M, Van Lente E, Degortes E, et al.
Orphanet J Rare Dis
. 2023 Jun;
18(1):144.
PMID: 37308991
Background: The Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA) was established in 2013 with the intention of developing a coordinated mechanism between volunteering EU stakeholders and developers of...
2.
Kossmeier M, Themanns M, Hatapoglu L, Kogler B, Keuerleber S, Lichtenecker J, et al.
Front Pharmacol
. 2021 Sep;
12:726758.
PMID: 34483937
Reimbursement decisions on new medicines require an assessment of their value. In Austria, when applying for reimbursement of new medicines, pharmaceutical companies are also obliged to submit forecasts of future...
3.
Tian Y, Reichardt B, Dunkler D, Hronsky M, Winkelmayer W, Bucsics A, et al.
Sci Rep
. 2020 Apr;
10(1):5964.
PMID: 32249786
Generic medications offer substantial potential cost savings to health systems compared to their branded counterparts. In Europe and the US, they are only approved if they are bioequivalent to the...
4.
Wilking N, Bucsics A, Kandolf Sekulovic L, Kobelt G, Laslop A, Makaroff L, et al.
ESMO Open
. 2019 Dec;
4(6):e000550.
PMID: 31798977
The Central European Cooperative Oncology Group (CECOG) and 'ESMO Open-Cancer Horizons' roundtable discussion brought together stakeholders from several European Union (EU) countries involved in drug development, drug authorisation and reimbursement...
5.
Vella Bonanno P, Bucsics A, Simoens S, Martin A, Oortwijn W, Gulbinovic J, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2019 Jan;
19(3):251-261.
PMID: 30696372
In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU'. A...
6.
Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe C, Ferrario A, et al.
Front Public Health
. 2018 Dec;
6:328.
PMID: 30568938
There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever...
7.
Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, Furst J, et al.
Orphanet J Rare Dis
. 2018 Nov;
13(1):184.
PMID: 30396361
Background: Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU). Objectives: To identify the different methods for public funding of OMPs in order to...
8.
Eichler H, Barker R, Bedlington N, Bouvy J, Broekmans A, Bucsics A, et al.
Nat Rev Drug Discov
. 2018 Jul;
17(12):845-846.
PMID: 29977052
No abstract available.
9.
Bochenek T, Abilova V, Alkan A, Asanin B, de Miguel Beriain I, Besovic Z, et al.
Front Pharmacol
. 2018 Feb;
8:942.
PMID: 29403372
Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency of patient care, as well...
10.
Vella Bonanno P, Ermisch M, Godman B, Martin A, Van Den Bergh J, Bezmelnitsyna L, et al.
Front Pharmacol
. 2017 Sep;
8:497.
PMID: 28878667
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines...